{"id":"adebrelimab-combined-with-chemotherapy","safety":{"commonSideEffects":[{"rate":"3%","effect":"Pneumonitis"},{"rate":"5%","effect":"Hypothyroidism"},{"rate":"10%","effect":"Diarrhea"},{"rate":"15%","effect":"Fatigue"},{"rate":"12%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adebrelimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to recognize and attack cancer cells more effectively.","oneSentence":"Immune checkpoint inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:19:21.599Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT07392541","phase":"PHASE1, PHASE2","title":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Carcinoma","enrollment":29},{"nctId":"NCT07479628","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-04-01","conditions":"Thymic Carcinoma","enrollment":31},{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":"Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT07454720","phase":"PHASE2, PHASE3","title":"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Locally Advanced Resectable Rectal Cancer","enrollment":165},{"nctId":"NCT07452601","phase":"PHASE2","title":"Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT06452602","phase":"PHASE2","title":"Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":60},{"nctId":"NCT07437898","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study","status":"RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2024-09-03","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT07430579","phase":"NA","title":"Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The Second Hospital of Shandong University","startDate":"2024-12-09","conditions":"Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events","enrollment":25},{"nctId":"NCT06943235","phase":"PHASE2","title":"Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-25","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07118527","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-18","conditions":"Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":600},{"nctId":"NCT06610734","phase":"PHASE2","title":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-12-23","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":202},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07388095","phase":"NA","title":"Adebrelimab Neoadjuvant Treatment for Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-15","conditions":"ESCC","enrollment":22},{"nctId":"NCT07229625","phase":"PHASE3","title":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-01-21","conditions":"Advanced Biliary Tract Cancer","enrollment":604},{"nctId":"NCT07266025","phase":"PHASE2","title":"Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-30","conditions":"Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors","enrollment":30},{"nctId":"NCT07110571","phase":"PHASE2","title":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":200},{"nctId":"NCT07241793","phase":"PHASE2","title":"Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent","enrollment":96},{"nctId":"NCT07284992","phase":"PHASE2","title":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","status":"RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-09-12","conditions":"Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy","enrollment":208},{"nctId":"NCT07281209","phase":"PHASE2","title":"A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-12","conditions":"NSCLC","enrollment":40},{"nctId":"NCT06925516","phase":"PHASE2","title":"A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-01-22","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":38},{"nctId":"NCT06177522","phase":"PHASE2","title":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2025-11-30","conditions":"Pancreatic Cancer, Neoadjuvant Therapy","enrollment":30},{"nctId":"NCT07170995","phase":"PHASE3","title":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-10-22","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":460},{"nctId":"NCT07230301","phase":"PHASE2","title":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","status":"NOT_YET_RECRUITING","sponsor":"Sizhen Wang","startDate":"2025-11-30","conditions":"Pancreatic Cancer Metastatic","enrollment":20},{"nctId":"NCT06869213","phase":"PHASE2","title":"A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-03-31","conditions":"Esophageal Cancer (EsC)","enrollment":30},{"nctId":"NCT07200154","phase":"PHASE2","title":"Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-30","conditions":"Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy","enrollment":30},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT06385678","phase":"PHASE1, PHASE2","title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-05","conditions":"Advanced KRAS G12D Mutant Solid Tumors","enrollment":47},{"nctId":"NCT06247956","phase":"PHASE2","title":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-11","conditions":"Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma","enrollment":153},{"nctId":"NCT06420908","phase":"NA","title":"Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"WITHDRAWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-05-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT07137039","phase":"PHASE2","title":"Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-08-20","conditions":"Locally Advanced Hypopharyngeal Cancer","enrollment":34},{"nctId":"NCT07137858","phase":"PHASE2","title":"Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy","enrollment":70},{"nctId":"NCT07135544","phase":"PHASE2","title":"A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","status":"RECRUITING","sponsor":"Yongjun Chen","startDate":"2025-08-14","conditions":"Biliary Tract Cancer, Biliary Tract Cancer (CCA)","enrollment":37},{"nctId":"NCT07112833","phase":"PHASE2","title":"A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-08-10","conditions":"Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT07105592","phase":"PHASE1, PHASE2","title":"A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-13","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT07069270","phase":"PHASE2","title":"A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09-01","conditions":"Vunakizumab, Adebrelimab, Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT07062328","phase":"PHASE2","title":"A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-10","conditions":"Biliary Tract Carcinoma","enrollment":39},{"nctId":"NCT06893887","phase":"NA","title":"Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Nanjing Tianyinshan Hospital","startDate":"2025-05-22","conditions":"Hepatocellular Carcinoma(HCC)","enrollment":300},{"nctId":"NCT07007364","phase":"PHASE2","title":"Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial","status":"RECRUITING","sponsor":"Jun Jia","startDate":"2025-06-19","conditions":"Early-Stage Oral Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06500208","phase":"PHASE2","title":"Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-01","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT07035392","phase":"PHASE2","title":"Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2025-06-20","conditions":"Adebrelimab (SHR-1316), NSCLC, Chemotherapy","enrollment":32},{"nctId":"NCT06913777","phase":"PHASE3","title":"Neoadjuvant SNF Precision Therapy Phase III","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-08","conditions":"Neoadjuvant Therapy","enrollment":404},{"nctId":"NCT06277791","phase":"PHASE2","title":"The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-08-19","conditions":"Clinical IVb Stage Oral Squamous Cell Carcinomas Patients","enrollment":35},{"nctId":"NCT06985602","phase":"PHASE2","title":"Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-05-16","conditions":"Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":30},{"nctId":"NCT06914050","phase":"PHASE2","title":"Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04","conditions":"Lung Cancer, Small Cell, Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":30},{"nctId":"NCT06483282","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jin Ying","startDate":"2024-06-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":38},{"nctId":"NCT06908668","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-31","conditions":"HER2-Negative Locally Advanced Breast Cancer","enrollment":170},{"nctId":"NCT06885814","phase":"PHASE2","title":"Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-06-06","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06861777","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"YIN LI","startDate":"2025-03","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":474},{"nctId":"NCT06853678","phase":"NA","title":"Second-line Immunotherapy for ES-SCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-02-28","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":30},{"nctId":"NCT06208462","phase":"PHASE2","title":"Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":33},{"nctId":"NCT06282445","phase":"PHASE2","title":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2024-03-01","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06784206","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02","conditions":"Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy, Simultaneous Radiotherapy and Chemotherapy","enrollment":30},{"nctId":"NCT06349889","phase":"PHASE2","title":"Adebrelimab and Chemoradiotherapy in High-risk LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-23","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer","enrollment":50},{"nctId":"NCT06775275","phase":"PHASE2","title":"A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2024-09-24","conditions":"Resectable Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT06771154","phase":"PHASE2","title":"Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-01","conditions":"Recurrent/Metastatic Endometrial Cancer","enrollment":140},{"nctId":"NCT06768307","phase":"PHASE2","title":"Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02","conditions":"SCLC, Extensive Stage, Immunotherapy, Chemotherapy","enrollment":60},{"nctId":"NCT06765616","phase":"PHASE2","title":"Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Feng Tian","startDate":"2024-01-01","conditions":"Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy","enrollment":31},{"nctId":"NCT06764368","phase":"PHASE2","title":"Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-01-01","conditions":"Neuroendocrine Tumors","enrollment":39},{"nctId":"NCT06737913","phase":"PHASE2","title":"HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":78},{"nctId":"NCT06467617","phase":"PHASE2","title":"Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC","status":"RECRUITING","sponsor":"Beijing Chest Hospital, Capital Medical University","startDate":"2024-08-14","conditions":"Non Small Cell Lung Cancer","enrollment":35},{"nctId":"NCT06684158","phase":"PHASE2","title":"Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-30","conditions":"GC/GEJC","enrollment":70},{"nctId":"NCT06672133","phase":"PHASE3","title":"Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Jinming Yu","startDate":"2024-12","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":524},{"nctId":"NCT06663059","phase":"PHASE2","title":"Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-10-01","conditions":"Esophageal Cancer","enrollment":80},{"nctId":"NCT04516681","phase":"PHASE3","title":"Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-12-01","conditions":"Colorectal Cancer, Vitamin C, GLUT3","enrollment":400},{"nctId":"NCT06614621","phase":"PHASE2","title":"A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-02-01","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT06510660","phase":"PHASE2","title":"Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-04-11","conditions":"Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers","enrollment":48},{"nctId":"NCT06599775","phase":"PHASE2","title":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-10","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT06592287","phase":"PHASE1, PHASE2","title":"The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xianglin Yuan","startDate":"2024-09-30","conditions":"Advanced Gastric Cancer","enrollment":66},{"nctId":"NCT06600841","phase":"PHASE2","title":"Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-10-01","conditions":"Platinum-resistant Ovarian Cancer (PROC), Immunotherapy","enrollment":37},{"nctId":"NCT06562920","phase":"PHASE2","title":"Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-07-24","conditions":"Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT06475326","phase":"PHASE2","title":"Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-05","conditions":"Pancreatic Cancer","enrollment":87},{"nctId":"NCT06514118","phase":"","title":"Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2024-04-17","conditions":"Small-cell Lung Cancer, Residual Tumor, Radiation","enrollment":70},{"nctId":"NCT06513221","phase":"PHASE2","title":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-25","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06508229","phase":"PHASE2","title":"Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":65},{"nctId":"NCT06506292","phase":"PHASE2","title":"A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-01","conditions":"Adebrelimab (SHR-1316), XELOX, GC/GEJC","enrollment":25},{"nctId":"NCT06405061","phase":"PHASE2","title":"Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-05-01","conditions":"Adebrelimab, Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06298968","phase":"PHASE2","title":"Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-04-26","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":38},{"nctId":"NCT06485544","phase":"PHASE2","title":"Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-07-01","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":104},{"nctId":"NCT04562337","phase":"PHASE2","title":"SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-10-01","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":67},{"nctId":"NCT06482788","phase":"PHASE2","title":"Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-22","conditions":"Esophagogastric Junction Adenocarcinoma","enrollment":26},{"nctId":"NCT06482008","phase":"PHASE2","title":"HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-06-19","conditions":"Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT06454448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-15","conditions":"Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer","enrollment":20},{"nctId":"NCT06478264","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2024-07-13","conditions":"Esophageal Small Cell Carcinoma","enrollment":40},{"nctId":"NCT06455410","phase":"PHASE2","title":"GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-06-18","conditions":"Nasopharyngeal Carcinoma","enrollment":216},{"nctId":"NCT06470633","phase":"PHASE2","title":"To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-01","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":29},{"nctId":"NCT06464614","phase":"PHASE2","title":"Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2024-07-15","conditions":"Esophageal Cancer","enrollment":54},{"nctId":"NCT06415669","phase":"PHASE2","title":"A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-05-19","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06389500","phase":"PHASE2","title":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-05-01","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT06280508","phase":"PHASE2","title":"Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-01","conditions":"Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence","enrollment":40},{"nctId":"NCT06375317","phase":"PHASE2","title":"HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure","status":"NOT_YET_RECRUITING","sponsor":"Yehua Shen","startDate":"2024-04-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06339619","phase":"PHASE2","title":"Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-11","conditions":"Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT06339216","phase":"PHASE2","title":"A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-03-20","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT06335355","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2024-03","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":401},{"nctId":"NCT06323265","phase":"","title":"A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-03-26","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT06306560","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-03-15","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":40},{"nctId":"NCT06299371","phase":"PHASE2","title":"Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2024-04-15","conditions":"Non Small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06266832","phase":"PHASE2","title":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-01-01","conditions":"Rectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06229067","phase":"PHASE2","title":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Adebrelimab combined with chemotherapy","genericName":"Adebrelimab combined with chemotherapy","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Immune checkpoint inhibitor Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}